CoChat

Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology

Alves, Sandro, Churlaud, Guillaume, Klatzmann, David, Cartier, Nathalie · 2017 · Brain
Cited by 33

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Sir, We are appreciative of Dansokho, Aucouturier and Dorothée’s interest in our recent article entitled ‘Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice’ (Alves et al., 2017) and for their constructive comments. As they noted, our work showed that low-dose interleukin-2 (IL-2) rescued memory defects of mice treated at a time they have established Alzheimer’s disease, extending their own work in which they showed the prevention of Alzheimer’s disease by IL-2. They used APPPS1 mice treated at Week 6, the onset of amyloid-β deposition, and monitored the treatment effects at Month 4; we used the APP/PS1ΔE9 mouse model treated at Month 8, and monitored treatment effects at Month 13. We also reported additional novel findings regarding the potential of IL-2 in Alzheimer’s disease: (i) IL-2 levels are decreased in hippocampal biopsies from Alzheimer’s disease patients; (ii) IL-2 treatment expanded regulatory T cells (Tregs) not only in the periphery (Dansokho et al., 2016), but also in the brain; and (iii) IL-2’s beneficial effects on memory could be correlated with decreased hippocampal amyloid plaques and the amyloid Aβ42/40 ratio, as well as improved synaptic plasticity and spine density (Alves et al., 2017). Dansokho and colleagues then make comments on some of our observations that could be interpreted as being at variance with theirs or some from the literature, to which we respond below. They first point to a study reporting an increase of IL-2 levels (129%) in hippocampal homogenates (Araujo and Lapchak, 1994), a potential discrepancy with our observation of a 50% decrease of IL-2 levels in hippocampal biopsies from severely affected Alzheimer’s disease patients (Thal 5/Braak VI). However, the study referred to used radio-immunoassays with antisera specific for IL-2, while we used a commercial assay based on monoclonal antibody. We observed that IL-2 decrease was heterogeneous among Alzheimer’s disease patients, with a strong decrease observed in three out of five Alzheimer’s disease patients (Fig. 1A in Alves et al., 2017). Importantly, the levels of IL-2 remained relatively homogeneous among the five control individuals analysed. Furthermore, we evaluated IL-2 levels in five Thal 5/Braak VI Alzheimer’s disease patients, while no information regarding clinical stage is mentioned in the study of Araujo and Lapchak (1994). Larger studies with Alzheimer’s disease patients at different Braak stages (Braak et al., 2006) are warranted to further analyse IL-2 levels in hippocampal biopsies of Alzheimer’s disease patients. ELISA showing increased statistically significant concentration of IFN-γ in the hippocampus of APP/PS1ΔE9 mice treated with AAV-IL-2 relative to APP/PS1ΔE9 mice treated with the control vector (AAV-LUC). Samples used in this analysis are the same used for IL-2 assessment (see Fig. 2B in Alves et al., 2017). Dansokho and colleagues then point to the fact that we observed improved learning of IL-2-treated wild-type mice during the 5-day acquisition phase in the Morris water maze place navigation task, relative to control mice, and despite no increased IL-2 hippocampal levels (Fig. 3A in Alves et al., 2017). Even though no increased IL-2 was observed in the hippocampus, IL-2 injection in wild-type mice induced increased Tregs in the brain. Besides, Dansokho and colleagues could also have noted that, in contrast, IL-2 did not improve the performance of Alzheimer’s disease mice during the learning phase. Similar results during the acquisition/learning phase have recently been observed in the same Alzheimer’s disease mouse model (APPPS1ΔE9), in which increased performance was found in littermates treated with AAV-APPsα relative to littermates injected with the control vector or to Alzheimer’s disease mice injected with either vector (Fol et al., 2016). These data suggest that therapies work differentially according to the physiological or pathological context. In a physiological context, IL-2 treatment could act as a memory enhancer; in an Alzheimer’s disease context, IL-2 treatment could exert only disease-modifying effects leading to restoration of memory abilities without promnesic properties. Hence, we believe that the probe tests, which evaluate spatial reference memory after the training trials, are more relevant to the study of IL-2’s impact on Alzheimer’s disease. These tests clearly showed beneficial effects of IL-2 during the memory consolidation period (Alves et al., 2017). Importantly, this improved memory performance correlates with tissue remodelling showing improved synaptic plasticity and rescued spine density in IL-2-treated Alzheimer’s disease mice (Alves et al., 2017), which was not addressed in Dansokho et al. (2016). Dansokho and colleagues then comment on the fact that our observed Treg increase in the brain of IL-2-treated Alzheimer’s disease mice does not tell us whether these cells are in the brain parenchyma or outside of th

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awx109

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 10

  1. 2017, Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice, Brain, 140, 826
  2. 1994, Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors, Neuroscience, 61, 745, 10.1016/0306-4522(94)90398-0 · DOI
  3. 2008, IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease, FASEB J, 22, 2843, 10.1096/fj.08-105866 · DOI · Paper page
  4. 2008, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, Brain, 131, 3299
  5. 2006, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry, Acta Neuropathol, 112, 389, 10.1007/s00401-006-0127-z · DOI · Paper page
  6. 2010, IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice, J Immunol, 184, 5333, 10.4049/jimmunol.0903382 · DOI · Paper page
  7. 2016, Regulatory T cells delay disease progression in Alzheimer-like pathology, Brain, 139, 1237, 10.1093/brain/awv408 · DOI · Paper page
  8. 2016, Viral gene transfer of APPsalpha rescues synaptic failure in an Alzheimer's disease mouse model, Acta Neuropathol, 131, 247, 10.1007/s00401-015-1498-9 · DOI · Paper page
  9. 2006, Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA, 103, 5048, 10.1073/pnas.0506209103 · DOI · Paper page
  10. 2003, Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain, J Neurochem, 87, 609, 10.1046/j.1471-4159.2003.02018.x · DOI · Paper page

Cited by

Metadata

Authors
Alves, S., Churlaud, G., Klatzmann, D., & Cartier, N.
Venue
Brain
Published
2017-05-12
Volume
140
Issue
7
Pages
e40-e40
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2612835152
Cited by
33
References
4
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.